Publications
5491 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 6543) poster #326; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- LUNGMAP
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 6505), abst 6505; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
The Medicaid Expansion of the Affordable Care Act and Participation of Patients with Medicaid in SWOG Cancer Clinical Trials
- Journal / Conference
- Prostate May 10. doi: 10.1002/pros.24369. Online ahead of print
- Year
- 2022
- Research Committee(s)
- Genitourinary
- PMID
- PMID35538398
- Study Number(s)
- CTSU/E3805
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
- Journal / Conference
- Cancer Epidemiology Biomarkers & Prevention May 4;31(5):1077-1089
- Year
- 2022
- Research Committee(s)
- Prevention and Epidemiology
- PMID
- PMID35438744
- PMC
- PMC9081195
- Study Number(s)
- S0000
Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 4522), poster 14; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
Association of DNA damage response (DDR) gene alterations (alts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 1518), poster 112; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1415CD
A Pragmatic Cluster-Randomized Trial of a Standing Physician Order Entry Intervention for Colony Stimulating Factor use among Patients at Intermediate Risk for Febrile Neutropenia (SWOG S1415CD)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 1525), poster 119; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1415CD
A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for cancer patients receiving myelosuppressive chemotherapy (SWOG S1415CD)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 4506), abst 4506; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle invasive bladder cancer in SWOG S1314
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4608), poster 94a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1937
A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClinicalTrials.gov NCT04579224)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 11013), poster 204; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022